يعرض 1 - 20 نتائج من 43 نتيجة بحث عن '"30 mg"', وقت الاستعلام: 0.99s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
  7. 7
    Academic Journal

    المصدر: Mesopotamia Journal of Agriculture, Vol 45, Iss 3, Pp 97-108 (2019)

    وصف الملف: electronic resource

  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
  14. 14
    Academic Journal

    المصدر: Cancer Urology; Том 12, № 3 (2016); 96-101 ; Онкоурология; Том 12, № 3 (2016); 96-101 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-3

    مصطلحات موضوعية: Castrate-resistant prostate cancer (CRPC) is one of the most complex and currently completely unsolved problems of oncourology. Possible novel treatment of CRPC is administration of Octreotide Long, long-acting somatostatin analogue. In this paper we have shown an experience of treatment with Octreotide Long 30 mg and dexamethasone in 69 CRPC patients from February 2014 to March 2016. We have assessed an efficacy and safety of the therapy. Age of patients ranged from 56 to 89 years, all patients had continued androgen deprivation. Response to the treatment was assessed clinically by the following factors: change in the level of prostate specific antigen (PSA) in serum, dynamics of indicators of general and biochemical blood tests, the level of pain syndrome and improvement in the patient’s quality of life. Total response to reduction and stabilization of PSA level was achieved in 70.9 % of patients. In general, the best results were observed in the group of patients treated with Octreotide Long before first-line chemotherapy with docetaxel. Tolerability of Octreotide Long in combination with dexamethasone in all cases was good. No significant side effects – neither hematological, nor clinical were noted. We also did not register any cases of drug discontinuation due to its intolerance, рак предстательной железы, заболеваемость, методы лечения, гормональная терапия, кастрационная резистентность, выживаемость, аналоги соматостатина, Октреотид-лонг, эффективность лечения, побочные эффекты

    وصف الملف: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/614/583; https://oncourology.abvpress.ru/oncur/article/view/614/650; Злокачественные новообразования в России в 2014 году(заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.А. Петровой. М., 2016. [Malignant neoplasms in Russia in 2012(morbidity and mortality). Ed. by: A.D. Kaprin, V.V. Starinskiy, G.A. Petrova. Moscow, 2014. (In Russ.)].; Князев Е.Н., Фомичева К.А., Нюшко К.М. и др. Актуальные вопросы молекулярной диагностики рака предстательной железы. Онкоурология 2014;(4):14–22. [Knyazev E.N., Fomicheva K.A., Nyushko K.M. et al. Topical issues of prostate cancer molecular diagnostics. Onkourologiya = Oncourology 2014;(4):14–22.(In Russ.)].; Нюшко К.М., Алексеев Б.Я., Калпинский А.С., Каприн А.Д. Антагонисты лютеинизирующего гормона рилизинг-гормона у больных раком предстательной железы. Стандартный подход и результаты инновационных исследований. Онкоурология 2014;(4):70–4. [Nyushko K.M., Alekseev B.Ya., Kalpinsky A.S., Kaprin A.D. Luteinizing hormone-releasing hormone antagonistsin patients with prostate cancer. Standard approach and results of innovational studies. Onkourologiya = Oncourology 2014;(4):70–4. (In Russ.)].; Мишугин С.В., Мордовин А.А., Ганов В.И. и др. Опыт применения аналога соматостатина длительного действия Октреотида-лонг при лечении кастрационно-резистентного рака предстательной железы. Онкология. Журнал им. П.А. Герцена 2016;5(1):31–5. [Мishugin S.V., Моrdovin А.А., Ganov V.I. et al. Experience of application of the long-acting somatostatine equivalent – octreotide-long at the treatment of the castration-resistant prostate cancer. Onkologiya. Zhurnal im. P.A. Gertsena = Оncology. P.A. Herzen Journal 2016;5 (1):31–5. (In Russ.)].; Мишугин С.В., Мордовин А.А., Грицкевич А.А., Русаков И.Г. Аналог соматостатина пролонгированного действия Октреотид-лонг у больных кастрационно-резистентным раком предстательной железы. Онкология. Журнал им. П.А. Герцена. 2014;3(5):53–6. [Мishugin S.V., Моrdovin А.А., Gritskevich А.А., Rusakov I.G. Long-acting somatostatine equivalent – octreotide-long at patients with castration-resistant prostate cancer. Onkologiya. Zhurnal im. P.A. Gertsena = Оncology. P.A. Herzen Journal 2014;3 (5):53–6. (In Russ.)].; Матвеев Б.П., Бухаркин Б.В., Калинин С.А. Лечение гормонорезистентного рака предстательной железы. В кн.: Материалы конференции «Онкологическая урология: от научных исследований к клинической практике (современные возможности лечения опухолей предстательной железы, мочевого пузыря и почки)». М., 2004. С. 28–31. [Маtveev B.P., Buharkin B.V., Kalinin S.А. Treatment of the hormone resistant prostate cancer. In the book: Маterials of the conference «Оncologic urology: from scientific studies to clinical practice (modern opportunities for the treatment of prostate, bladder and kidney tumors). Мoscow, 2004. Pp. 28–31. (In Russ.)].; Abrahamson Per-Anders. Revolutions in the management of hormone-refractory prostate cancer. Eur Urol 2003; Suppl. 2:1–2.; Crawford D.E., Rosenblum M., Ziada A.M. et al. Overview: hormone-refractory prostate cancer. Urology 1999;54(6A, Suppl.):1–7.; Клиническая онкоурология. Под ред. Б.П. Матвеева. М.: АБВ-пресс, 2011. С. 723–79.; Kish J., Bukkapatnam R. The treatment challenge of hormonerefractory prostate cancer. Cancer Care 2001;8(6): 487–95.; Русаков И.Г., Грицкевич А.А. Возможности аналогов соматостатина в лечении кастрационно-резистентного рака предстательной железы. Онкология. Журнал им. П.А. Герцена 2012;(1):73–6. [Rusakov I.G., Gritskevich А.А. Capabilities of somatostatine equivalents in the treatment of the castration-resistant prostate cancer. Onkologiya. Zhurnal im. P.A. Gertsena = Оncology. P.A. Herzen Journal 2012; (1):73–6. (In Russ.)].; Ковылина М.В., Прилепская Е.А., Сергейко И.П. и др. Значение выявления нейроэндокринной дифференцировки при раке предстательной железы. Онкоурология 2013;(4):43–6. 12. [Kovylinа М.V., Prilepskaya Е.А., Sergeykо I.P. et al. The value of revealing of the neuroendocrine differentiation at the prostate cancer. Onkourologiya = Оncourology 2013; (4):43– 6. (In Russ.)].; Аполихин О.И., Сивков А.В., Ефремов Г.Д. и др. Показатели хромогранина А сыворотки крови при различных заболеваниях предстательной железы. Экспериментальная и клиническая урология 2014;(1):2–7. [Аpolikhin О.I., Sivkov А.V., Еfremov G.D. et al. Chromogranine A indices of the blood serum at different prostate diseases. Eksperimental’naya i klinicheskaya urologiya = Experimental and Clinical Urology 2014; (1):2–7. (In Russ.)].; Ганов Д.И., Варламов С.А. Опыт применения Октреотида-лонг у па- циентов с кастрационно-рефрактерным раком предстательной железы. Онкоуро- логия 2011;(4):71–3. [Ganov D.I., Varlamov S.А. Experience of Octreotide-long administration to patients with the castration-refractory cancer of the prostate. Onkourologiya = Оncourology 2011;(4):71–3. (In Russ.)].; Алексеев Б.Я., Каприн А.Д., Нюшко К.М. Роль аналогов соматостатина в лечении больных гормонорефрактерным раком предстательной железы. Онкоурология 2011;(2):84–7. [Аlekseev B.Ya., Kaprin А.D., Nushkо К.М. The role of somatostatine equivalents in the treatment of patients with the castration-refractory cancer of the prostate. Onkourologiya = Оncourology 2011;(2):84–7. (In Russ.)].; Ганов Д.И., Варламов С.А. Первый опыт применения Октреотида-лонг у пациентов с гормонорефрактерным раком предстательной железы. Mатериалы IV конгресса РООУ. Онкоурология 2009:32. [Ganov D.I., Varlamov S.А. First experience of the Octreotide-long administration to patients with the hormone refractory cancer of the prostate. Mаterials of the IV ROOU congress. Onkourologiya = Оncourology 2009:32. (In Russ.)].; Алексеев Б.Я., Русаков И.Г., Каприн А.Д. и др. Аналоги соматостатина в лечении гормонорефрактерного рака предстательной железы до и после химиотерапии. Материалы V конгресса РООУ. Онкоурология 2010:34–5. [Аlekseev B.Ya., Rusakov I.G., Kaprin А.D. et al. Somatostatine equivalents in the treatment of the hormone refractory prostate cancer before and after the chemotherapy. Mаterials of the IV ROOU congress. Onkourologiya = Оncourology 2010:34–5. (In Russ.)].; Ганов Д.И., Варламов С.А., Лазарев А.Ф. Октреотид-лонг в лечении рака предстательной железы. Материалы V конгресса РООУ. Онкоурология 2010:48. [Ganov D.I., Varlamov S.А., Lazarev А.F. Оctreotide-long in the treaement of the prostate cancer. Mаterials of the V ROOU congress. Onkourologiya = Оncourology 2010:48. (In Russ.)].; Ганов Д.И., Варламов С.А. Октреотид-лонг и гормонорефрактерный метастатический рак предстательной железы. Материалы VI конгресса РООУ. Онкоурология 2011:69. [Ganov D.I., Varlamov S.А. Оctreotide-long and the hormone refractory metastatic prostate cancer. Onkourologiya = Оncourology 2011:69. (In Russ.)].; Березин П.Г. Кастрационно-рефрактерный рак предстательной железы: место Октреотида-лонг в лечении больных. Материалы VII конгресса РООУ. Онкоурология 2012:28–9. [Berezin P.G. Castration-refractory prostate cancer: place of Octreotide-long in the treatment of patients. Mаterials of the IV ROOU congress. Onkourologiya = Оncourology Оncourology 2012:28–9. (In Russ.)].; https://oncourology.abvpress.ru/oncur/article/view/614

  15. 15
    Academic Journal

    مصطلحات موضوعية: CASTRATE-RESISTANT PROSTATE CANCER (CRPC) IS ONE OF THE MOST COMPLEX AND CURRENTLY COMPLETELY UNSOLVED PROBLEMS OF ONCOUROLOGY. POSSIBLE NOVEL TREATMENT OF CRPC IS ADMINISTRATION OF OCTREOTIDE LONG,LONG-ACTING SOMATOSTATIN ANALOGUE. IN THIS PAPER WE HAVE SHOWN AN EXPERIENCE OF TREATMENT WITH OCTREOTIDE LONG 30 MG AND DEXAMETHASONE IN 69 CRPC PATIENTS FROM FEBRUARY 2014 TO MARCH 2016. WE HAVE ASSESSED AN EFFICACY AND SAFETY OF THE THERAPY. AGE OF PATIENTS RANGED FROM 56 TO 89 YEARS,ALL PATIENTS HAD CONTINUED ANDROGEN DEPRIVATION. RESPONSE TO THE TREATMENT WAS ASSESSED CLINICALLY BY THE FOLLOWING FACTORS: CHANGE IN THE LEVEL OF PROSTATE SPECIFIC ANTIGEN (PSA) IN SERUM,DYNAMICS OF INDICATORS OF GENERAL AND BIOCHEMICAL BLOOD TESTS,THE LEVEL OF PAIN SYNDROME AND IMPROVEMENT IN THE PATIENT'S QUALITY OF LIFE. TOTAL RESPONSE TO REDUCTION AND STABILIZATION OF PSA LEVEL WAS ACHIEVED IN 70.9 % OF PATIENTS. IN GENERAL,THE BEST RESULTS WERE OBSERVED IN THE GROUP OF PATIENTS TREATED WITH OCTREOTIDE LONG BEFORE FIRST-LINE CHEMOTHERAPY WITH DOCETAXEL. TOLERABILITY OF OCTREOTIDE LONG IN COMBINATION WITH DEXAMETHASONE IN ALL CASES WAS GOOD. NO SIGNIFICANT SIDE EFFECTS – NEITHER HEMATOLOGICAL,NOR CLINICAL WERE NOTED. WE ALSO DID NOT REGISTER ANY CASES OF DRUG DISCONTINUATION DUE TO ITS INTOLERANCE.,РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ,ЗАБОЛЕВАЕМОСТЬ,МЕТОДЫ ЛЕЧЕНИЯ,ГОРМОНАЛЬНАЯ ТЕРАПИЯ,КАСТРАЦИОННАЯ РЕЗИСТЕНТНОСТЬ,ВЫЖИВАЕМОСТЬ,АНАЛОГИ СОМАТОСТАТИНА,ОКТРЕОТИД-ЛОНГ,ЭФФЕКТИВНОСТЬ ЛЕЧЕНИЯ,ПОБОЧНЫЕ ЭФФЕКТЫ

    وصف الملف: text/html

  16. 16

    المصدر: Mesopotamia Journal of Agriculture, Vol 45, Iss 3, Pp 97-108 (2019)

  17. 17
  18. 18

    المصدر: Onkourologiâ, Vol 12, Iss 3, Pp 96-101 (2016)

    مصطلحات موضوعية: medicine.medical_specialty, Urology, medicine.medical_treatment, Octreotide, castrate-resistant prostate cancer (crpc) is one of the most complex and currently completely unsolved problems of oncourology. possible novel treatment of crpc is administration of octreotide long, long-acting somatostatin analogue. in this paper we have shown an experience of treatment with octreotide long 30 mg and dexamethasone in 69 crpc patients from february 2014 to march 2016. we have assessed an efficacy and safety of the therapy. age of patients ranged from 56 to 89 years, all patients had continued androgen deprivation. response to the treatment was assessed clinically by the following factors: change in the level of prostate specific antigen (psa) in serum, dynamics of indicators of general and biochemical blood tests, the level of pain syndrome and improvement in the patient’s quality of life. total response to reduction and stabilization of psa level was achieved in 70.9 % of patients. in general, the best results were observed in the group of patients treated with octreotide long before first-line chemotherapy with docetaxel. tolerability of octreotide long in combination with dexamethasone in all cases was good. no significant side effects – neither hematological, nor clinical were noted. we also did not register any cases of drug discontinuation due to its intolerance, urologic and male genital diseases, Gastroenterology, Prostate cancer, Quality of life, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Dexamethasone, Chemotherapy, business.industry, medicine.disease, Surgery, Prostate-specific antigen, Oncology, Tolerability, Docetaxel, Nephrology, Medicine, business, medicine.drug

  19. 19
    Academic Journal

    المساهمون: Feustel, C (reprint author), APOGEPHA Arzneimittel GmbH, Kyffhauserstr 27, D-01309 Dresden, Germany., Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai, Peoples R China., Beijing Boai Hosp, Beijing, Peoples R China., Minist Hlth, Beijing Hosp, Beijing, Peoples R China., Zhejiang Univ, Coll Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China., Hebei Med Univ, Hosp 2, Shijiazhuang, Peoples R China., Guangzhou First Municipal Peoples Hosp, Guangzhou, Guangdong, Peoples R China., Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China., Wuxi Peoples Hosp, Wuxi, Peoples R China., Peking Univ, Hosp 1, Beijing, Peoples R China., Fudan Univ, Huashan Hosp, Shanghai, Peoples R China., Peking Univ, Hosp 3, Beijing, Peoples R China., China Acad Chinese Med Sci, Basic Med Inst, Beijing, Peoples R China., APOGEPHA Arzneimittel GmbH, Kyffhauserstr 27, D-01309 Dresden, Germany., Capital Univ Med Sci, Beijing Chaoyang Hosp, Beijing, Peoples R China., Med Univ Innsbruck, Innsbruck, Austria.

    المصدر: PubMed ; SCI

    Relation: BJU INTERNATIONAL.2017,119(1),148-157.; 1389937; http://hdl.handle.net/20.500.11897/434083; WOS:000390401200024

  20. 20